Local Pressure Shores Up Drug Firms (India)
This article was originally published in PharmAsia News
Estimates released by global investment giant Goldman Sachs project India will be the world's fifth-largest market for pharmaceuticals by 2020. According to the analysis, companies who have already established themselves in Indian will see the biggest returns as a result of this growth. Sun Pharmaceuticals and Nicholas Piramal were cited as two drug-makers with the best prospects to mine India's soon-to-be booming market. In fact, Nicolas Piramal has recently upped its sales force in the country to 3,300 and its pipeline now covers nine therapies. Another corporation looking to cash-in on India's future drug market is Glenmark. The company already boasts an extensive drug portfolio as well as a sales team with 1,900 representatives. Goldman Sachs said the steep increase in drug sales would come as a result of the country's high rates of urbanization and the proliferation of chronic "lifestyle" diseases. (Click here for more
You may also be interested in...
Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.
Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection
Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.